175 related articles for article (PubMed ID: 22884956)
41. Predictive Value of 18 F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer.
Ko WS; Kim SJ
Clin Nucl Med; 2023 Jul; 48(7):574-580. PubMed ID: 36976654
[TBL] [Abstract][Full Text] [Related]
42. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review.
Kwee RM
Radiology; 2010 Mar; 254(3):707-17. PubMed ID: 20177086
[TBL] [Abstract][Full Text] [Related]
43. Conventional 99mTc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses.
Kubo T; Furuta T; Sakuda T; Ochi M; Adachi N
Medicine (Baltimore); 2018 Dec; 97(51):e13308. PubMed ID: 30572434
[TBL] [Abstract][Full Text] [Related]
44. The utility of
Zhang Q; Xi Y; Li D; Yuan Z; Dong J
J Orthop Surg Res; 2020 Jun; 15(1):229. PubMed ID: 32571371
[TBL] [Abstract][Full Text] [Related]
45. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
46. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
[TBL] [Abstract][Full Text] [Related]
47. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
Quarles van Ufford HM; van Tinteren H; Stroobants SG; Riphagen II; Hoekstra OS
J Nucl Med; 2010 Oct; 51(10):1507-16. PubMed ID: 20847179
[TBL] [Abstract][Full Text] [Related]
48. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
Pakos EE; Fotopoulos AD; Ioannidis JP
J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
[TBL] [Abstract][Full Text] [Related]
50. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis.
Kyzas PA; Evangelou E; Denaxa-Kyza D; Ioannidis JP
J Natl Cancer Inst; 2008 May; 100(10):712-20. PubMed ID: 18477804
[TBL] [Abstract][Full Text] [Related]
51. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
52. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.
Wang Y; Zhang C; Liu J; Huang G
Breast Cancer Res Treat; 2012 Jan; 131(2):357-69. PubMed ID: 21960111
[TBL] [Abstract][Full Text] [Related]
53. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography.
Shiraishi K; Nomori H; Ohba Y; Kaji M; Mori T; Shibata H; Oya N; Sasaki J
Ann Thorac Cardiovasc Surg; 2010 Dec; 16(6):394-400. PubMed ID: 21263419
[TBL] [Abstract][Full Text] [Related]
54. 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis.
Zhu L; Wang N
Surg Oncol; 2013 Sep; 22(3):190-4. PubMed ID: 23849685
[TBL] [Abstract][Full Text] [Related]
55. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis.
Zou H; Zhao Y
Surg Oncol; 2013 Sep; 22(3):162-6. PubMed ID: 23747134
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
57. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis.
Zhang C; Tong J; Sun X; Liu J; Wang Y; Huang G
Int J Cancer; 2012 Dec; 131(11):2604-11. PubMed ID: 22447461
[TBL] [Abstract][Full Text] [Related]
58.
Kim K; Kim SJ
Hell J Nucl Med; 2021; 24(2):132-139. PubMed ID: 34352048
[TBL] [Abstract][Full Text] [Related]
59. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
60. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
